Moving gemcitabine/nab-paclitaxel to every-other-week dosing decreases infusion visits and may lessen cumulative toxicity, ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...
Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
The study of immune inflammatory responses centers on the intricate molecular pathways that both initiate and modulate these processes. Inflammation is ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), and BeiGene, Ltd ...
Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results